Etomoxir has been described as a selective inhibitor of CPT1 and thus has been widely used to examine the functional roles of fatty acid oxidation in multiple disease states including cardiac ischemia, heart failure, diabetes, and obesity. Here, CPT1A is linked to obesity due to melanocortin 4 receptor deficiency.